Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02094586 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
A Phase 3 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,146
- Enrollment target
NCT02094586 is a Phase 3 study that has completed, run by Bavarian Nordic. The registered enrollment target is 3,146 participants.
The verdict
NCT02094586, a Phase 3 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,146 participants
- Enrollment target
Study Summary
The primary goal of this Phase III study is to compare 3 lots for consistency of manufacture.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PXVX0200 Lot A
- BIOLOGICAL PXVX0200 Lot B
- BIOLOGICAL PXVX0200 Lot C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,146 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02094586
The ClinicalTrials.gov registry entry for NCT02094586 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02094586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02094586 about?
NCT02094586 is a clinical study titled "A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults". The primary goal of this Phase III study is to compare 3 lots for consistency of manufacture.
What is the current status of trial NCT02094586?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,146 participants. The study started on 2014-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02094586?
The interventions under investigation include: Placebo (BIOLOGICAL), PXVX0200 Lot A (BIOLOGICAL), PXVX0200 Lot B (BIOLOGICAL), PXVX0200 Lot C (BIOLOGICAL).
Who is sponsoring clinical trial NCT02094586?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.